Rituximab in Antimelanoma Differentiation-Associated Protein-5 Dermatomyositis with Interstitial Lung Disease.
Chiara SciroccoAndreina GubbiottiAlfredo SebastianiGian Domenico SebastianiPublished in: Case reports in rheumatology (2020)
In this paper, we report a challenging case of a middle-age woman who developed antimelanoma differentiation-associated protein-5 dermatomyositis (anti-MDA5 DM) with interstitial lung disease (ILD) and was successfully treated with rituximab (RTX), after failure of a first-line therapy.
Keyphrases
- interstitial lung disease
- systemic sclerosis
- rheumatoid arthritis
- diffuse large b cell lymphoma
- idiopathic pulmonary fibrosis
- chronic lymphocytic leukemia
- hodgkin lymphoma
- breast cancer cells
- case report
- type diabetes
- skeletal muscle
- stem cells
- adipose tissue
- cell death
- metabolic syndrome
- cell proliferation
- cell therapy
- weight loss
- smoking cessation